- Home
- SISI vs GLYC Comparison
SISI vs GLYC Comparison
Compare SISI & GLYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- GLYC
- Stock Information
- Founded
- SISI 1997
- GLYC 2003
- Country
- SISI China
- GLYC United States
- Employees
- SISI N/A
- GLYC N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- GLYC Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- GLYC Health Care
- Exchange
- SISI Nasdaq
- GLYC Nasdaq
- Market Cap
- SISI 17.9M
- GLYC 15.9M
- IPO Year
- SISI 2016
- GLYC 2014
- Fundamental
- Price
- SISI $0.89
- GLYC $0.21
- Analyst Decision
- SISI
- GLYC Hold
- Analyst Count
- SISI 0
- GLYC 3
- Target Price
- SISI N/A
- GLYC N/A
- AVG Volume (30 Days)
- SISI 128.8K
- GLYC 228.8K
- Earning Date
- SISI 05-14-2025
- GLYC 05-08-2025
- Dividend Yield
- SISI N/A
- GLYC N/A
- EPS Growth
- SISI N/A
- GLYC N/A
- EPS
- SISI N/A
- GLYC N/A
- Revenue
- SISI $11,072,553.00
- GLYC N/A
- Revenue This Year
- SISI N/A
- GLYC N/A
- Revenue Next Year
- SISI N/A
- GLYC N/A
- P/E Ratio
- SISI N/A
- GLYC N/A
- Revenue Growth
- SISI 145.88
- GLYC N/A
- 52 Week Low
- SISI $0.73
- GLYC $0.14
- 52 Week High
- SISI $117.65
- GLYC $3.02
- Technical
- Relative Strength Index (RSI)
- SISI 44.31
- GLYC 32.85
- Support Level
- SISI $0.85
- GLYC $0.24
- Resistance Level
- SISI $1.27
- GLYC $0.28
- Average True Range (ATR)
- SISI 0.16
- GLYC 0.02
- MACD
- SISI 0.02
- GLYC -0.01
- Stochastic Oscillator
- SISI 30.64
- GLYC 21.89
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About GLYC GlycoMimetics Inc.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.